News headlines about Genocea Biosciences (NASDAQ:GNCA) have trended somewhat negative on Tuesday, Alpha One reports. Alpha One, a subsidiary of Accern, ranks the sentiment of press coverage by analyzing more than twenty million news and blog sources in real time. Alpha One ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Genocea Biosciences earned a news impact score of -0.11 on Alpha One’s scale. Alpha One also assigned news stories about the biotechnology company an impact score of 75 out of 100, indicating that recent press coverage is likely to have an effect on the company’s share price in the next several days.
Here are some of the news stories that may have impacted Alpha One’s analysis:
- Brokerages Anticipate Genocea Biosciences, Inc. (GNCA) Will Announce Earnings of -$0.46 Per Share (americanbankingnews.com)
- Active Stock on Watch: Genocea Biosciences Inc (GNCA) – Evergreen Caller (evergreencaller.com)
- Genocea Biosciences, Inc. (GNCA) Given Consensus Rating of “Buy” by Analysts (americanbankingnews.com)
- Today Genocea Biosciences Inc (GNCA) Stock Crashes – Weekly Register (weeklyregister.com)
Genocea Biosciences (GNCA) opened at 5.15 on Tuesday. The company’s market capitalization is $146.79 million. Genocea Biosciences has a 52 week low of $3.28 and a 52 week high of $7.29. The firm has a 50-day moving average of $6.01 and a 200-day moving average of $5.30.
Genocea Biosciences (NASDAQ:GNCA) last issued its quarterly earnings results on Thursday, May 4th. The biotechnology company reported ($0.48) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.54) by $0.06. Analysts anticipate that Genocea Biosciences will post ($1.89) EPS for the current fiscal year.
Separately, Zacks Investment Research upgraded shares of Genocea Biosciences from a “hold” rating to a “buy” rating and set a $6.75 target price on the stock in a research note on Tuesday, May 16th. One research analyst has rated the stock with a hold rating and five have given a buy rating to the stock. The stock presently has an average rating of “Buy” and an average price target of $16.02.
Genocea Biosciences Company Profile
Genocea Biosciences, Inc, is harnessing the power of T cell immunity to develop vaccines and immunotherapies company. The Company uses its discovery platform, AnTigen Lead Acquisition System (ATLAS), to design vaccines and immunotherapies that act, in part, through T cell (or cellular) immune responses.
Receive News & Ratings for Genocea Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.